MedTrace Logo

Sevoflurane and Percutaneous Coronary Intervention by Stent

NCT02671084 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 701

Last updated 2020-04-28

No results posted yet for this study

Summary

Increase in CK-MB after percutaneous coronary angioplasty more than 100% of baseline can represents a problem to the patients resulting in increase of morbidity and mortality.

Patients submitted of coronary angioplasty procedures can release in varying degrees of creatine kinase, MB isoform (CK - MB), on the order of 30% of all angioplasty.

Possibly patients who will receive sevoflurane experience a higher level of cardiac cell protection with lower incidence in the release of CK - MB values in excess of 100% baseline.

Conditions

Interventions

DRUG

sevoflurane

compare effect of sevoflurane when administered before PCI

Sponsors & Collaborators

  • Instituto Dante Pazzanese de Cardiologia

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2020-04-30
Completion
2020-04-30

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02671084 on ClinicalTrials.gov